Download PDF
Semin Respir Crit Care Med 2016; 37(05): 736-749
DOI: 10.1055/s-0036-1592111
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Metastatic Lung Cancer: Emerging Therapeutic Strategies

Sana Saif Ur Rehman
1   Division of Oncology, Department of Medicine, Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri
,
Suresh S. Ramalingam
2   Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia
› Author Affiliations
Further Information

Publication History

Publication Date:
12 October 2016 (online)

    Permissions and Reprints

Abstract

Advanced stage nonsmall cell lung cancer had been treated mainly with platinum-based doublet chemotherapy, and other cytotoxic agents that offered significant survival advantage over best supportive care, until recently. Modest improvements were achieved with the addition of antibodies targeting the vascular endothelial growth factor, and the introduction of maintenance chemotherapy. Improvements in our knowledge of lung cancer biology have shifted the current treatment paradigm from being based on histology to one based on molecular biomarkers. Identification of potentially targetable driver mutations in a subgroup of these patients, pertaining to genes directing cell signaling pathways involved in proliferation and survival, has been the single most influential development in the treatment of lung cancer in the last two decades. Personalized medicine based on driver mutations offers enhanced efficacy at the expense of relatively minimal toxicity burden. Targeting the epidermal growth factor receptor pathway in patients with an activating mutation results in substantial improvement in patient outcome. Similarly, targeting ALK (anaplastic lymphoma kinase) fusion gene with first- and second-generation inhibitors results in improved efficacy over chemotherapy. For certain other mutations such as MET exon 14 and BRAF, promising inhibitory strategies are being investigated. In addition, the recent emergence of immune checkpoint inhibitors to reverse exhaustion of T cells has been a major breakthrough in rapidly changing the therapeutic landscape for lung cancer. This article reviews the role of systemic therapy in advanced stage lung cancer.

Keywords

lung cancer - NSCLC - metastatic - chemotherapy - targeted therapy - EGFR - anaplastic lymphoma kinase
 

  • References

  • 1 Ferlay J, Soerjomataram I, Dikshit R , et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136 (5) E359-E386
    CrossrefPubMedGoogle Scholar
  • 2 Howlader N, Noone AM, Krapcho M , et al. SEER Cancer Statistics Review, 1975–2013, National Cancer Institute. Bethesda, MD. Based on November 2015 SEER data submission posted on the SEER website. Available at http://seer.cancer.gov/csr/1975_2013/ . Released April 15, 2016
    PubMed
  • 3 Brahmer J, Reckamp KL, Baas P , et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015; 373 (2) 123-135
    CrossrefPubMedGoogle Scholar
  • 4 Garon EB, Rizvi NA, Hui R , et al; KEYNOTE-001 Investigators. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015; 372 (21) 2018-2028
    CrossrefPubMedGoogle Scholar
  • 5 Leighl NB, Rekhtman N, Biermann WA , et al. Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cancer/association for molecular pathology guideline. J Clin Oncol 2014; 32 (32) 3673-3679
    CrossrefPubMedGoogle Scholar
  • 6 Rapp E, Pater JL, Willan A , et al. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer—report of a Canadian multicenter randomized trial. J Clin Oncol 1988; 6 (4) 633-641
    PubMedGoogle Scholar
  • 7 Burdett S, Stephens R, Stewart L , et al; NSCLC Meta-Analyses Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 2008; 26 (28) 4617-4625
    CrossrefPubMedGoogle Scholar
  • 8 Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995; 311 (7010) 899-909
    CrossrefPubMedGoogle Scholar
  • 9 Delbaldo C, Michiels S, Syz N, Soria JC, Le Chevalier T, Pignon JP. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. JAMA 2004; 292 (4) 470-484
    CrossrefPubMedGoogle Scholar
  • 10 Azzoli CG, Baker Jr S, Temin S , et al; American Society of Clinical Oncology. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009; 27 (36) 6251-6266
    CrossrefPubMedGoogle Scholar
  • 11 Reck M, Popat S, Reinmuth N, De Ruysscher D, Kerr KM, Peters S ; ESMO Guidelines Working Group. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014; 25 (Suppl. 03) iii27-iii39
    CrossrefPubMedGoogle Scholar
  • 12 Schiller JH, Harrington D, Belani CP , et al; Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346 (2) 92-98
    CrossrefPubMedGoogle Scholar
  • 13 Kelly K, Crowley J, Bunn Jr PA , et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non—small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001; 19 (13) 3210-3218
    CrossrefPubMedGoogle Scholar
  • 14 Fossella F, Pereira JR, von Pawel J , et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 2003; 21 (16) 3016-3024
    CrossrefPubMedGoogle Scholar
  • 15 Scagliotti GV, De Marinis F, Rinaldi M , et al; Italian Lung Cancer Project. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002; 20 (21) 4285-4291
    CrossrefPubMedGoogle Scholar
  • 16 Rudd RM, Gower NH, Spiro SG , et al. Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group. J Clin Oncol 2005; 23 (1) 142-153
    CrossrefPubMedGoogle Scholar
  • 17 Booton R, Lorigan P, Anderson H , et al. A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1). Ann Oncol 2006; 17 (7) 1111-1119
    CrossrefPubMedGoogle Scholar
  • 18 Belani CP, Lee JS, Socinski MA , et al. Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer. Ann Oncol 2005; 16 (7) 1069-1075
    CrossrefPubMedGoogle Scholar
  • 19 Ohe Y, Ohashi Y, Kubota K , et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 2007; 18 (2) 317-323
    PubMedGoogle Scholar
  • 20 Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, Tanimoto M. Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 2004; 22 (19) 3852-3859
    CrossrefPubMedGoogle Scholar
  • 21 Ardizzoni A, Boni L, Tiseo M , et al; CISCA (CISplatin versus CArboplatin) Meta-analysis Group. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 2007; 99 (11) 847-857
    CrossrefPubMedGoogle Scholar
  • 22 Baggstrom MQ, Stinchcombe TE, Fried DB, Poole C, Hensing TA, Socinski MA. Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis. J Thorac Oncol 2007; 2 (9) 845-853
    CrossrefPubMedGoogle Scholar
  • 23 Socinski MA, Schell MJ, Peterman A , et al. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol 2002; 20 (5) 1335-1343
    CrossrefPubMedGoogle Scholar
  • 24 Smith IE, O'Brien ME, Talbot DC , et al. Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol 2001; 19 (5) 1336-1343
    CrossrefPubMedGoogle Scholar
  • 25 von Plessen C, Bergman B, Andresen O , et al. Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer. Br J Cancer 2006; 95 (8) 966-973
    CrossrefPubMedGoogle Scholar
  • 26 Park JO, Kim SW, Ahn JS , et al. Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer. J Clin Oncol 2007; 25 (33) 5233-5239
    CrossrefPubMedGoogle Scholar
  • 27 Scagliotti GV, Parikh P, von Pawel J , et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26 (21) 3543-3551
    CrossrefPubMedGoogle Scholar
  • 28 Patel JD, Socinski MA, Garon EB , et al. PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. J Clin Oncol 2013; 31 (34) 4349-4357
    CrossrefPubMedGoogle Scholar
  • 29 Socinski MA, Bondarenko I, Karaseva NA , et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol 2012; 30 (17) 2055-2062
    CrossrefPubMedGoogle Scholar
  • 30 Folkman J. What is the evidence that tumors are angiogenesis dependent?. J Natl Cancer Inst 1990; 82 (1) 4-6
    CrossrefPubMedGoogle Scholar
  • 31 Sandler A, Gray R, Perry MC , et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355 (24) 2542-2550
    CrossrefPubMedGoogle Scholar
  • 32 Johnson DH, Fehrenbacher L, Novotny WF , et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004; 22 (11) 2184-2191
    CrossrefPubMedGoogle Scholar
  • 33 Reck M, von Pawel J, Zatloukal P , et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009; 27 (8) 1227-1234
    CrossrefPubMedGoogle Scholar
  • 34 Garon EB, Ciuleanu TE, Arrieta O , et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 2014; 384 (9944) 665-673
    CrossrefPubMedGoogle Scholar
  • 35 Scagliotti G, Novello S, von Pawel J , et al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 2010; 28 (11) 1835-1842
    CrossrefPubMedGoogle Scholar
  • 36 Paz-Ares LG, Biesma B, Heigener D , et al; NSCLC [non–small-cell lung cancer] Research Experience Utilizing Sorafenib (NExUS) Investigators Study Group. Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer. J Clin Oncol 2012; 30 (25) 3084-3092
    CrossrefPubMedGoogle Scholar
  • 37 Paz-Ares LG, Hirsch V, Zhang L , et al. Monotherapy administration of sorafenib in patients with non-small cell lung cancer: phase III, randomized, double-blind, placebo-controlled mission trial. J Thorac Oncol 2015; 10 (12) 1745-1753
    CrossrefPubMedGoogle Scholar
  • 38 Socinski MA, Wang XF, Baggstrom MQ , et al. Sunitinib (S) switch maintenance in advanced non-small cell lung cancer (NSCLC): an ALLIANCE (CALGB 30607), randomized, placebo-controlled phase III trial. J Clin Oncol 2014; 32: 5s
    CrossrefPubMedGoogle Scholar
  • 39 Socinski MA, Novello S, Brahmer JR , et al. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 2008; 26 (4) 650-656
    CrossrefPubMedGoogle Scholar
  • 40 Novello S, Scagliotti GV, Rosell R , et al. Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer. Br J Cancer 2009; 101 (9) 1543-1548
    CrossrefPubMedGoogle Scholar
  • 41 Scagliotti GV, Krzakowski M, Szczesna A , et al. Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial. J Clin Oncol 2012; 30 (17) 2070-2078
    CrossrefPubMedGoogle Scholar
  • 42 Goss GD, Arnold A, Shepherd FA , et al. Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study. J Clin Oncol 2010; 28 (1) 49-55
    CrossrefPubMedGoogle Scholar
  • 43 Scagliotti GV, Vynnychenko I, Park K , et al. International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1. J Clin Oncol 2012; 30 (23) 2829-2836
    CrossrefPubMedGoogle Scholar
  • 44 Weiss JM, Villaruz LC, Socinski MA , et al. A single-arm phase II trial of pazopanib in patients with advanced non-small cell lung cancer with non-squamous histology with disease progression on bevacizumab containing therapy. Lung Cancer 2014; 86 (2) 288-290
    CrossrefPubMedGoogle Scholar
  • 45 Schiller JH, Larson T, Ou SH , et al. Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study. J Clin Oncol 2009; 27 (23) 3836-3841
    CrossrefPubMedGoogle Scholar
  • 46 Heymach JV, Paz-Ares L, De Braud F , et al. Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 2008; 26 (33) 5407-5415
    CrossrefPubMedGoogle Scholar
  • 47 de Boer RH, Arrieta Ó, Yang CH , et al. Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. J Clin Oncol 2011; 29 (8) 1067-1074
    CrossrefPubMedGoogle Scholar
  • 48 Herbst RS, Sun Y, Eberhardt WE , et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol 2010; 11 (7) 619-626
    CrossrefPubMedGoogle Scholar
  • 49 Natale RB, Thongprasert S, Greco FA , et al. Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2011; 29 (8) 1059-1066
    CrossrefPubMedGoogle Scholar
  • 50 Lee JS, Hirsh V, Park K , et al. Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR). J Clin Oncol 2012; 30 (10) 1114-1121
    CrossrefPubMedGoogle Scholar
  • 51 Roth GJ, Heckel A, Colbatzky F , et al. Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120). J Med Chem 2009; 52 (14) 4466-4480
    CrossrefPubMedGoogle Scholar
  • 52 Reck M, Kaiser R, Mellemgaard A , et al; LUME-Lung 1 Study Group. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol 2014; 15 (2) 143-155
    CrossrefPubMedGoogle Scholar
  • 53 Goss GD, Spaans JN. Epidermal growth factor receptor inhibition in the management of squamous cell carcinoma of the lung. Oncologist 2016; 21 (2) 205-213
    CrossrefPubMedGoogle Scholar
  • 54 Pirker R, Pereira JR, Szczesna A , et al; FLEX Study Team. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009; 373 (9674) 1525-1531
    CrossrefPubMedGoogle Scholar
  • 55 Thatcher N, Hirsch FR, Luft AV , et al; SQUIRE Investigators. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. Lancet Oncol 2015; 16 (7) 763-774
    CrossrefPubMedGoogle Scholar
  • 56 Paz-Ares L, Mezger J, Ciuleanu T , et al. Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomized, controlled phase 3 study. Lancet Oncol 2015; 16: 328-337
    CrossrefPubMedGoogle Scholar
  • 57 Fidias PM, Dakhil SR, Lyss AP , et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2009; 27 (4) 591-598
    CrossrefPubMedGoogle Scholar
  • 58 Ciuleanu T, Brodowicz T, Zielinski C , et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009; 374 (9699) 1432-1440
    CrossrefPubMedGoogle Scholar
  • 59 Paz-Ares LG, de Marinis F, Dediu M , et al. PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol 2013; 31 (23) 2895-2902
    CrossrefPubMedGoogle Scholar
  • 60 Cappuzzo F, Ciuleanu T, Stelmakh L , et al; SATURN investigators. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010; 11 (6) 521-529
    CrossrefPubMedGoogle Scholar
  • 61 Johnson BE, Kabbinavar F, Fehrenbacher L , et al. ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 2013; 31 (31) 3926-3934
    CrossrefPubMedGoogle Scholar
  • 62 Pérol M, Chouaid C, Pérol D , et al. Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2012; 30 (28) 3516-3524
    CrossrefPubMedGoogle Scholar
  • 63 Zinner RG, Obasaju CK, Spigel DR , et al. PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients with advanced nonsquamous non-small-cell lung cancer. J Thorac Oncol 2015; 10 (1) 134-142
    CrossrefPubMedGoogle Scholar
  • 64 Belani CP, Barstis J, Perry MC , et al. Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. J Clin Oncol 2003; 21 (15) 2933-2939
    CrossrefPubMedGoogle Scholar
  • 65 Brodowicz T, Krzakowski M, Zwitter M , et al; Central European Cooperative Oncology Group CECOG. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer 2006; 52 (2) 155-163
    CrossrefPubMedGoogle Scholar
  • 66 Shepherd FA, Dancey J, Ramlau R , et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18 (10) 2095-2103
    CrossrefPubMedGoogle Scholar
  • 67 Hanna N, Shepherd FA, Fossella FV , et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22 (9) 1589-1597
    CrossrefPubMedGoogle Scholar
  • 68 Peterson P, Park K, Fossella F, Gatzemeier U, John W, Scagliotti G. Is pemetrexed more effective in patients with non-squamous histology? A retrospective analysis of a phase III trial of pemetrexed vs docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC) [abstract]. Eur J Cancer Suppl 2007; 5 (4) 363-364
    PubMedGoogle Scholar
  • 69 Shepherd FA, Rodrigues Pereira J, Ciuleanu T , et al; National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353 (2) 123-132
    CrossrefPubMedGoogle Scholar
  • 70 Kim ES, Hirsh V, Mok T , et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008; 372 (9652) 1809-1818
    CrossrefPubMedGoogle Scholar
  • 71 Ciuleanu T, Stelmakh L, Cicenas S , et al. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncol 2012; 13 (3) 300-308
    CrossrefPubMedGoogle Scholar
  • 72 Garassino MC, Martelli O, Broggini M , et al; TAILOR trialists. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol 2013; 14 (10) 981-988
    CrossrefPubMedGoogle Scholar
  • 73 Kawaguchi T, Ando M, Asami K , et al. Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA). J Clin Oncol 2014; 32 (18) 1902-1908
    CrossrefPubMedGoogle Scholar
  • 74 Karampeazis A, Voutsina A, Souglakos J , et al. Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 study. Cancer 2013; 119 (15) 2754-2764
    CrossrefPubMedGoogle Scholar
  • 75 Gahr S, Stoehr R, Geissinger E , et al. EGFR mutational status in a large series of Caucasian European NSCLC patients: data from daily practice. Br J Cancer 2013; 109 (7) 1821-1828
    CrossrefPubMedGoogle Scholar
  • 76 Fukuoka M, Wu YL, Thongprasert S , et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 2011; 29 (21) 2866-2874
    CrossrefPubMedGoogle Scholar
  • 77 Han JY, Park K, Kim SW , et al. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol 2012; 30 (10) 1122-1128
    CrossrefPubMedGoogle Scholar
  • 78 Mitsudomi T, Morita S, Yatabe Y , et al. Up-dated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib with cisplatin plus docetaxel as the first-line treatment for patients with advanced non-small-cell lung cancer harboring mutations of the epidermal growth factor receptor. J Clin Oncol 2012; 30 (Suppl):abstract 7521
    PubMedGoogle Scholar
  • 79 Inoue A, Kobayashi K, Maemondo M , et al; North-East Japan Study Group. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann Oncol 2013; 24 (1) 54-59
    CrossrefPubMedGoogle Scholar
  • 80 Zhou C, Wu YL, Chen G , et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011; 12 (8) 735-742
    CrossrefPubMedGoogle Scholar
  • 81 Rosell R, Carcereny E, Gervais R , et al; Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; 13 (3) 239-246
    CrossrefPubMedGoogle Scholar
  • 82 Sequist LV, Yang JC, Yamamoto N , et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013; 31 (27) 3327-3334
    CrossrefPubMedGoogle Scholar
  • 83 Wu YL, Zhou C, Hu CP , et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol 2014; 15 (2) 213-222
    CrossrefPubMedGoogle Scholar
  • 84 Solca F, Dahl G, Zoephel A , et al. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther 2012; 343 (2) 342-350
    CrossrefPubMedGoogle Scholar
  • 85 Lee CK, Brown C, Gralla RJ , et al. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. J Natl Cancer Inst 2013; 105 (9) 595-605
    CrossrefPubMedGoogle Scholar
  • 86 NCCN clinical practice guidelines in oncology (NCCN Guidelines). Non-small cell lung cancer NCCN evidence blocks (version 4. Available at https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf . Accessed January 6, 2016
    PubMedGoogle Scholar
  • 87 Park K, Tan EH, O'Byrne K , et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol 2016; 17 (5) 577-589
    CrossrefPubMedGoogle Scholar
  • 88 Gainor JF, Shaw AT. Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer. J Clin Oncol 2013; 31 (31) 3987-3996
    CrossrefPubMedGoogle Scholar
  • 89 Sequist LV, Waltman BA, Dias-Santagata D , et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011; 3 (75) 75ra26
    CrossrefPubMedGoogle Scholar
  • 90 Arcila ME, Oxnard GR, Nafa K , et al. Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin Cancer Res 2011; 17 (5) 1169-1180
    CrossrefPubMedGoogle Scholar
  • 91 Pao W, Miller VA, Politi KA , et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005; 2 (3) e73
    CrossrefPubMedGoogle Scholar
  • 92 Cross DA, Ashton SE, Ghiorghiu S , et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov 2014; 4 (9) 1046-1061
    CrossrefPubMedGoogle Scholar
  • 93 Jänne PA, Yang JC, Kim DW , et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med 2015; 372 (18) 1689-1699
    CrossrefPubMedGoogle Scholar
  • 94 Yang J, Ahn M, Ramalingam S , et al. AZD9291 in pre-treated T790M positive advanced NSCLC: AURA study phase II extension cohort. J Clin Oncol 2015; 10 (Suppl. 02) S319
    PubMedGoogle Scholar
  • 95 Mitsudomi T, Tsa C, Shepherd F , et al. AZD9291 in pre-treated T790M positive advanced NSCLC: AURA2 phase II study. J Clin Oncol 2015; 10 (Suppl. 02) S320
    PubMedGoogle Scholar
  • 96 Sequist LV, Soria JC, Goldman JW , et al. Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med 2015; 372 (18) 1700-1709
    CrossrefPubMedGoogle Scholar
  • 97 Park K, Lee JS, Lee KH , et al. Updated safety and efficacy results from phase I/II study of HM61713 in patients (pts) with EGFR mutation positive non-small cell lung cancer (NSCLC) who failed previous EGFR-tyrosine kinase inhibitor (TKI). J Clin Oncol 33, 2015 (suppl; abstr 8084).
    PubMedGoogle Scholar
  • 98 Goto Y, Nokihara H, Murakami H , et al. ASP8273, a mutant-selective irreversible EGFR inhibitor in patients (pts) with NSCLC harboring EGFR activating mutations: preliminary results of first-in-human phase I study in Japan. ASCO Meet Abstr 2015; 33 (Suppl): abstract 8014
    PubMedGoogle Scholar
  • 99 Yu HA, Oxnard GR, Spira AI , et al. Phase I dose escalation study of ASP8273, a mutant-selective irreversible EGFR inhibitor, in subjects with EGFR mutation positive NSCLC. ASCO Meet Abstr 2015; 33 (Suppl): abstract 8083
    PubMedGoogle Scholar
  • 100 Tan DS-W, Seto T, Leighl NB , et al. First-in-human phase I study of EGF816, a third generation, mutant-selective EGFR tyrosine kinase inhibitor, in advanced non-small cell lung cancer (NSCLC) harboring T790M. ASCO Meet Abstr 2015; 33 (Suppl): abstract 8013
    PubMedGoogle Scholar
  • 101 Niederst MJ, Hu H, Mulvey HE , et al. The allelic context of the C797S mutation acquired upon treatment with third-generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies. Clin Cancer Res 2015; 21 (17) 3924-3933
    CrossrefPubMedGoogle Scholar
  • 102 Song HN, Jung KS, Yoo KH , et al. Acquired C797S mutation upon treatment with a T790M-specific third-generation EGFR inhibitor (HM61713) in non-small cell lung cancer. J Thorac Oncol 2016; 11 (4) e45-e47
    CrossrefPubMedGoogle Scholar
  • 103 Thress KS, Paweletz CP, Felip E , et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med 2015; 21 (6) 560-562
    CrossrefPubMedGoogle Scholar
  • 104 Yu HA, Tian SK, Drilon AE , et al. Acquired resistance of EGFR-mutant lung cancer to a T790M-specific EGFR inhibitor: emergence of a third mutation (C797S) in the EGFR tyrosine kinase domain. JAMA Oncol 2015; 1 (7) 982-984
    CrossrefPubMedGoogle Scholar
  • 105 Jänne PA, Wang X, Socinski MA , et al. Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial. J Clin Oncol 2012; 30 (17) 2063-2069
    CrossrefPubMedGoogle Scholar
  • 106 Sugawara S, Oizumi S, Minato K , et al; North East Japan Study Group and Tokyo Cooperative Oncology Group. Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902. Ann Oncol 2015; 26 (5) 888-894
    CrossrefPubMedGoogle Scholar
  • 107 Cheng Y, Murakami H, Yang PC , et al. Randomized trial of gefitinib with and without pemetrexed as first-line therapy in East-Asian patients with advanced NS NSCLC with EGFR mutations. Paper presented at the 16th World Conference on Lung Cancer, September 6–9, 2015, Denver, CO
    PubMedGoogle Scholar
  • 108 Inoue A, Hosomi Y, Maemondo M , et al. NEJ009 trial: a randomized phase III study of gefitinib (G) in combination with carboplatin (C) plus pemetrexed (P) versus G alone in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) with EGFR mutation. J Clin Oncol 2014; 32 (Suppl): abstract TPS813 1
    CrossrefPubMedGoogle Scholar
  • 109 Wu YL, Lee JS, Thongprasert S , et al. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial. Lancet Oncol 2013; 14 (8) 777-786
    CrossrefPubMedGoogle Scholar
  • 110 Soda M, Choi YL, Enomoto M , et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448 (7153) 561-566
    CrossrefPubMedGoogle Scholar
  • 111 Shaw AT, Yeap BY, Mino-Kenudson M , et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009; 27 (26) 4247-4253
    CrossrefPubMedGoogle Scholar
  • 112 Cui JJ, Tran-Dubé M, Shen H , et al. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med Chem 2011; 54 (18) 6342-6363
    CrossrefPubMedGoogle Scholar
  • 113 Christensen JG, Zou HY, Arango ME , et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther 2007; 6 (12 Pt 1) 3314-3322
    CrossrefPubMedGoogle Scholar
  • 114 Kwak EL, Bang YJ, Camidge DR , et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010; 363 (18) 1693-1703
    CrossrefPubMedGoogle Scholar
  • 115 Camidge DR, Bang YJ, Kwak EL , et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012; 13 (10) 1011-1019
    CrossrefPubMedGoogle Scholar
  • 116 Kim DW, Ahn M-J, Shi Y , et al. Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC). J Clin Oncol 2012; 30: 7533
    PubMedGoogle Scholar
  • 117 Solomon BJ, Mok T, Kim DW , et al; PROFILE 1014 Investigators. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 2014; 371 (23) 2167-2177
    CrossrefPubMedGoogle Scholar
  • 118 Katayama R, Shaw AT, Khan TM , et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci Transl Med 2012; 4 (120) 120ra17
    CrossrefPubMedGoogle Scholar
  • 119 Doebele RC, Pilling AB, Aisner DL , et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res 2012; 18 (5) 1472-1482
    CrossrefPubMedGoogle Scholar
  • 120 Choi YL, Soda M, Yamashita Y , et al; ALK Lung Cancer Study Group. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 2010; 363 (18) 1734-1739
    CrossrefPubMedGoogle Scholar
  • 121 Kim D-W, Mehra R, Tan DSW , et al. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. Lancet Oncol 2016; 17 (4) 452-463
    CrossrefPubMedGoogle Scholar
  • 122 Mok T, Spigel D, Felip E , et al. ASCEND-2: a single-arm, open-label, multicenter phase 2 study of ceritinib in adult patients (pts) with ALK-rearranged (ALK + ) non-small cell lung cancer (NSCLC) previously treated with chemotherapy and crizotinib (CRZ). J Clin Oncol 2015; 33 (Suppl): abstract 8059
    PubMedGoogle Scholar
  • 123 Sakamoto H, Tsukaguchi T, Hiroshima S , et al. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell 2011; 19 (5) 679-690
    CrossrefPubMedGoogle Scholar
  • 124 Seto T, Kiura K, Nishio M , et al. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. Lancet Oncol 2013; 14 (7) 590-598
    CrossrefPubMedGoogle Scholar
  • 125 Gadgeel SM, Gandhi L, Riely GJ , et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Lancet Oncol 2014; 15 (10) 1119-1128
    CrossrefPubMedGoogle Scholar
  • 126 Nokihara H, Hida T, Kondo M , et al. Alectinib (ALC) versus crizotinib (CRZ) in ALK-inhibitor naive ALK-positive non-small cell lung cancer (ALK + NSCLC): Primary results from the J-ALEX study. J Clin Oncol 2016; 34 (Suppl): abstract 9008
    PubMedGoogle Scholar
  • 127 Friboulet L, Li N, Katayama R , et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov 2014; 4 (6) 662-673
    CrossrefPubMedGoogle Scholar
  • 128 Camidge D, Bazhenova L, Salgia R , et al. Safety and efficacy of brigatinib (AP26113) in advanced malignancies, including ALK+ non-small cell lung cancer (NSCLC). J Clin Oncol 2015; 33(Suppl) : abstract 8062
    PubMedGoogle Scholar
  • 129 Solomon BJ, Bauer TM, Felip E , et al. Safety and efficacy of lorlatinib (PF-06463922) from the dose-escalation component of a study in patients with advanced ALK+ or ROS1 + non-small cell lung cancer (NSCLC). J Clin Oncol 2016; 34 (Suppl): abstract 9009
    PubMedGoogle Scholar
  • 130 Horn L, Infante J, Blumenschein G , et al. A phase I trial of X-396, a novel ALK inhibitor, in patients with advanced solid tumors. J Clin Oncol 2014; 32(Suppl) : abstract 8030
    PubMedGoogle Scholar
  • 131 Arkenau H, Sachdev J, Mita M , et al. Phase (Ph) 1/2a study of TSR-011, a potent inhibitor of ALK and TRK, in advanced solid tumors including crizotinib-resistant ALK positive non-small cell lung cancer. J Clin Oncol 2015; 33(Suppl) : abstract 8063
    PubMedGoogle Scholar
  • 132 De Braud FG, Niger M, Damian S , et al. Alka-372–001: first-in-human, phase I study of entrectinib – an oral pan-trk, ROS1, and ALK inhibitor – in patients with advanced solid tumors with relevant molecular alterations. J Clin Oncol 2015; 33 (Suppl): abstract 2517
    PubMedGoogle Scholar
  • 133 Patel M, Bauer T, Liu S , et al. STARTRK-1: phase 1/2a study of entrectinib, an oral pan-Trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations. J Clin Oncol 2015; 33 (Suppl): abstract 2596
    PubMedGoogle Scholar
  • 134 Bergethon K, Shaw AT, Ou SH , et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 2012; 30 (8) 863-870
    CrossrefPubMedGoogle Scholar
  • 135 Shaw AT, Ou SH, Bang YJ , et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 2014; 371 (21) 1963-1971
    CrossrefPubMedGoogle Scholar
  • 136 Engelman JA, Settleman J. Acquired resistance to tyrosine kinase inhibitors during cancer therapy. Curr Opin Genet Dev 2008; 18 (1) 73-79
    CrossrefPubMedGoogle Scholar
  • 137 Song A, Kim TM, Kim DW , et al. Molecular changes associated with acquired resistance to crizotinib in ROS1-rearranged non-small cell lung cancer. Clin Cancer Res 2015; 21 (10) 2379-2387
    CrossrefPubMedGoogle Scholar
  • 138 Zou HY, Li Q, Engstrom LD , et al. PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations. Proc Natl Acad Sci U S A 2015; 112 (11) 3493-3498
    CrossrefPubMedGoogle Scholar
  • 139 Paik PK, Arcila ME, Fara M , et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol 2011; 29 (15) 2046-2051
    CrossrefPubMedGoogle Scholar
  • 140 Cardarella S, Ogino A, Nishino M , et al. Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer. Clin Cancer Res 2013; 19 (16) 4532-4540
    CrossrefPubMedGoogle Scholar
  • 141 Hyman DM, Puzanov I, Subbiah V , et al. Vemurafenib in multiple non melanoma cancers with BRAF V600 mutations. N Engl J Med 2015; 373 (8) 726-736
    CrossrefPubMedGoogle Scholar
  • 142 Planchard D, Besse B, Groen HJ , et al. An open-label phase II trial of dabrafenib (D) in combination with trametinib (T) in patients (pts) with previously treated BRAF V600E–mutant advanced non-small cell lung cancer (NSCLC; BRF113928). J Clin Oncol 2016; 34 (Suppl): abstract 107
    PubMedGoogle Scholar
  • 143 Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012; 489 (7417) 519-525
    CrossrefPubMedGoogle Scholar
  • 144 Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 2014; 511 (7511) 543-550
    CrossrefPubMedGoogle Scholar
  • 145 Camidge DR, Ou SI, Shapiro G , et al. Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC). ASCO Meet Abstr 2014; 32: 8001
    PubMedGoogle Scholar
  • 146 Paik PK, Drilon A, Fan PD , et al. Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. Cancer Discov 2015; 5 (8) 842-849
    CrossrefPubMedGoogle Scholar